STOCK TITAN

[6-K] Can-Fite BioPharma Ltd. Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K

Can-Fite BioPharma Ltd. furnished a Notice and Proxy Statement, a Proxy Card for ordinary shareholders, and a Voting Instruction Card for American Depositary Shareholders in connection with a Special General Meeting of Shareholders. The report is dated October 3, 2025 and is signed by Motti Farbstein, who is listed as Chief Executive Officer and Chief Financial Officer. The filing incorporates prior registration statements by reference to the extent not superseded.

Can-Fite BioPharma Ltd. ha fornito una Notifica e Procura, una scheda di procura per gli azionisti ordinari, e una scheda di istruzioni per il voto per gli azionisti depositari americani in relazione a una Riunione Generale Straordinaria degli Azionisti. Il rapporto è datato 3 ottobre 2025 ed è firmato da Motti Farbstein, indicato come Amministratore Delegato e Direttore Finanziario. La presentazione incorpora, per rinvio, le precedenti dichiarazioni di registrazione non superate.

Can-Fite BioPharma Ltd. presentó una Notificación y Declaración de Poder, una Tarjeta de Poder para accionistas ordinarios, y una Tarjeta de Instrucciones de Voto para accionistas de ADS en relación con una Junta General Extraordinaria de Accionistas. El informe está fechado el 3 de octubre de 2025 y está firmado por Motti Farbstein, quien figura como Director General y Director Financiero. El archivo incorpora, por referencia, declaraciones de registro anteriores en la medida en que no hayan sido superadas.

Can-Fite BioPharma Ltd.은 보통주 주주를 위한 공지 및 위임장, 위임장 카드, 및 미국 예탁주주를 위한 투표 지침 카드를 제공했습니다. 이는 주주 특별 일반회의와 관련이 있습니다. 보고서는 2025년 10월 3일로 날짜가 기재되어 있으며, 모티 파브스타인이 CEO 겸 CFO로 기재되어 있습니다. 제출은 구독을 포함하는 이전 등록 서류를 상향 참조로 포함합니다.

Can-Fite Biopharma Ltd. a fourni une Notification et Déclaration de procuration, une Carte de procuration pour les actionnaires ordinaires, et une Carte d'instructions de vote pour les actionnaires en actions de dépôt américain (ADS) dans le cadre d'une Réunion générale extraordinaire des actionnaires. Le rapport est daté du 3 octobre 2025 et est signé par Motti Farbstein, qui est indiqué comme Directeur Général et Directeur Financier. Le dépôt incorpore, par référence, les déclarations d'enregistrement antérieures dans la mesure où elles n'ont pas été remplacées.

Can-Fite BioPharma Ltd. legte eine Mitteilung und Proxy-Verlautbarung, eine Proxy-Karte für Stammaktionäre und eine Stimmanweisungskarte für ADR-Inhaber im Zusammenhang mit einer außerordentlichen Hauptversammlung der Aktionäre vor. Der Bericht ist datiert auf 3. Oktober 2025 und von Motti Farbstein unterschrieben, der als Chief Executive Officer und Chief Financial Officer geführt wird. Die Einreichung bezieht frühere Registrierungsunterlagen nach Maßgabe der nicht übertretenen.

قدمت شركة Can-Fite BioPharma Ltd. إشعار وبيان تفويض، وبطاقة تفويض للمساهمين العاديين، وبطاقة تعليمات التصويت للمساهمين في شهادات الإيداع الأمريكية فيما يتعلق بـالجمعية العامة الخاصة للمساهمين. والتقرير مؤرّخ بـ3 أكتوبر 2025 وموقع من موتّي فربستين، المدرج كمدير تنفيذي ومدير مالي. تم تضمين الملف بالاعتماد على بيانات تسجيل سابقة بقدر ما لم يتم استبدالها.

Can-Fite BioPharma Ltd. 提供了一个通知与代理声明、一个普通股股东代理权卡,以及一个投票指示卡,面向美国存托股股东,涉及一次股东特别大会。该报告日期为2025年10月3日,由Motti Farbstein签署,他被列为首席执行官兼首席财务官。该备案按引用方式包含先前的注册声明,前提是未被替代。

Positive
  • None.
Negative
  • None.

Can-Fite BioPharma Ltd. ha fornito una Notifica e Procura, una scheda di procura per gli azionisti ordinari, e una scheda di istruzioni per il voto per gli azionisti depositari americani in relazione a una Riunione Generale Straordinaria degli Azionisti. Il rapporto è datato 3 ottobre 2025 ed è firmato da Motti Farbstein, indicato come Amministratore Delegato e Direttore Finanziario. La presentazione incorpora, per rinvio, le precedenti dichiarazioni di registrazione non superate.

Can-Fite BioPharma Ltd. presentó una Notificación y Declaración de Poder, una Tarjeta de Poder para accionistas ordinarios, y una Tarjeta de Instrucciones de Voto para accionistas de ADS en relación con una Junta General Extraordinaria de Accionistas. El informe está fechado el 3 de octubre de 2025 y está firmado por Motti Farbstein, quien figura como Director General y Director Financiero. El archivo incorpora, por referencia, declaraciones de registro anteriores en la medida en que no hayan sido superadas.

Can-Fite BioPharma Ltd.은 보통주 주주를 위한 공지 및 위임장, 위임장 카드, 및 미국 예탁주주를 위한 투표 지침 카드를 제공했습니다. 이는 주주 특별 일반회의와 관련이 있습니다. 보고서는 2025년 10월 3일로 날짜가 기재되어 있으며, 모티 파브스타인이 CEO 겸 CFO로 기재되어 있습니다. 제출은 구독을 포함하는 이전 등록 서류를 상향 참조로 포함합니다.

Can-Fite Biopharma Ltd. a fourni une Notification et Déclaration de procuration, une Carte de procuration pour les actionnaires ordinaires, et une Carte d'instructions de vote pour les actionnaires en actions de dépôt américain (ADS) dans le cadre d'une Réunion générale extraordinaire des actionnaires. Le rapport est daté du 3 octobre 2025 et est signé par Motti Farbstein, qui est indiqué comme Directeur Général et Directeur Financier. Le dépôt incorpore, par référence, les déclarations d'enregistrement antérieures dans la mesure où elles n'ont pas été remplacées.

Can-Fite BioPharma Ltd. legte eine Mitteilung und Proxy-Verlautbarung, eine Proxy-Karte für Stammaktionäre und eine Stimmanweisungskarte für ADR-Inhaber im Zusammenhang mit einer außerordentlichen Hauptversammlung der Aktionäre vor. Der Bericht ist datiert auf 3. Oktober 2025 und von Motti Farbstein unterschrieben, der als Chief Executive Officer und Chief Financial Officer geführt wird. Die Einreichung bezieht frühere Registrierungsunterlagen nach Maßgabe der nicht übertretenen.

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

 

For the Month of October 2025

 

001-36203

(Commission File Number)

 

CAN-FITE BIOPHARMA LTD.

(Exact name of Registrant as specified in its charter)

 

26 Ben Gurion Street

Ramat Gan 5257346, Israel

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F þ Form 40-F

 

This Report on Form 6-K (including exhibits thereto) is hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File Nos. 333-227753333-271384 and 333-278525) and Form F-3 (File Nos. 333-236064333-274316333-262055333-276000 and 333-281872), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

 

 

 

 

 

On October 3, 2025, Can-Fite BioPharma Ltd. (the “Company”) announced that it will hold a Special General Meeting of Shareholders on November 3, 2025, at 3.00 p.m. (Israel time) at the Company’s offices at 26 Ben Gurion Street, Ramat Gan, Israel. In connection with the meeting, the Company furnishes the following documents:

 

  1. A copy of the Notice and Proxy Statement with respect to the Company’s Special General Meeting of Shareholders describing the proposal to be voted upon at the meeting, the procedure for voting in person or by proxy at the meeting and various other details related to the meeting, attached hereto as Exhibit 99.1;

 

  2. A form of Proxy Card whereby holders of ordinary shares of the Company may vote at the meeting without attending in person, attached hereto as Exhibit 99.2; and

 

  3. A form of Voting Instruction Card whereby holders of American Depositary Shares of the Company may vote at the meeting without attending in person, attached hereto as Exhibit 99.3.

 

1

 

 

Exhibit Index

 

Exhibit No.

 

Description

     
99.1   Notice and Proxy Statement with respect to the Company’s Special General Meeting of Shareholders
     
99.2   Proxy Card for holders of ordinary shares with respect to the Company’s Special General Meeting of Shareholders
     
99.3   Voting Instruction Card for American Depositary Shareholders with respect to the Company’s Special General Meeting of Shareholders

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date: October 3, 2025 By: /s/ Motti Farbstein
    Motti Farbstein
    Chief Executive Officer and Chief Financial Officer

 

 

3

 

 

FAQ

What did Can-Fite BioPharma (CANF) file in this 6-K?

The company furnished a Notice and Proxy Statement, a Proxy Card for ordinary shareholders, and a Voting Instruction Card for American Depositary Shareholders.

What is the date on the Can-Fite BioPharma (CANF) current report?

The report is dated October 3, 2025.

Who signed the Can-Fite BioPharma (CANF) 6-K?

The filing is signed by Motti Farbstein, identified as Chief Executive Officer and Chief Financial Officer.

Is the 6-K disclosing any transactions or financial data?

No. The filing furnishes meeting materials and incorporates prior registration statements by reference; it does not include financial tables or transaction details.

Who should use the Proxy Card and Voting Instruction Card in this filing?

Ordinary shareholders should use the Proxy Card, while holders of American Depositary Shares should use the Voting Instruction Card.
Can-Fite BioPharma Ltd.

NYSE:CANF

CANF Rankings

CANF Latest News

CANF Latest SEC Filings

CANF Stock Data

10.28M
17.07M
5.89%
1.13%
Biotechnology
Healthcare
Link
Israel
Ramat Gan